Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gallium Ga 68-edotreotide

A radioconjugate consisting of the octreotide derivative edotreotide labeled with gallium 68 (Ga-68) with potential application in somatostatin receptor (SSTR) imaging in conjunction with positron emission tomography (PET). Similar to octreotide, gallium Ga 68-edotreotide binds to SSTRs, especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells and their metastases, thereby allowing for imaging of SSTR-expressing cells upon PET. Gallium Ga 68-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelating the substituted octreotide to Ga-68 via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:68Ga-DOTA-d-Phe1-Tyr3-octreotide
68Ga-DOTA-TOC
Ga-68 DOTA0-Tyr3-octreotide
Ga-68 DOTATOC
Ga-68-[Tyr3]-octreotide
Ga-68-DOTA-TOC
Ga-68-DOTA-tyr(3)-octreotide
gallium Ga 68-DOTATOC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search